Medindia LOGIN REGISTER
Medindia
Advertisement

Novel Experimental Agent Benefits Chronic Lymphocytic Leukemia Patients

by Sheela Philomena on December 12, 2011 at 12:25 PM
 Novel Experimental Agent Benefits Chronic Lymphocytic Leukemia Patients

PCI-32765 - a B cell receptor inhibitor is highly active and well tolerated in patients with chronic lymphocytic leukemia (CLL), reveals report.

"PCI-32765, one of a new class of experimental drugs called B cell receptor inhibitors, has shown impressive potential in this clinical trial for its effectiveness and particularly for its relatively minimal toxicity," said lead investigator Susan O'Brien, M.D., professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

Advertisement

According to the National Cancer Institute's Surveillance Epidemiology and End Results database, an estimated 14,570 people will receive a diagnosis of CLL in 2011 and about 4,380 patients will die of the disease.

Six-month progression free survival of 90-92 percent

Of 27 CLL patients treated at a dose of 420 milligrams daily, 70 percent had complete or partial remission at 10.2 months of median follow-up. Six-month progression-free survival was 92 percent. Patients received a median three prior treatments before entering the clinical trial.
Advertisement

At a higher dose of 840 mg, 44 percent of 34 patients achieved complete or partial remission at 6.5 months median follow-up, similar to the response rate of the lower-dose cohort at 6.2 months. Progression free survival at 6 months was 90 percent. Study participants had received a median of five prior treatments.

Overall, five patients (8 percent) of the 61 from both arms had progressive disease and 50 (82 percent) remained on the therapy.

Drug does not suppress blood cell production

CLL presently is treated with combination chemotherapies that can cause myelosuppression - inhibited bone marrow function leading to decreased production of blood cells. The resulting susceptibility to infection can be a problem for patients, O'Brien said.

"PCI-32765 is not myelosuppressive. The main side effect is mild diarrhea that is usually self-limiting," O'Brien said.

Chronic lymphocytic leukemia is caused by overproduction of defective B cell lymphocytes, white blood cells that fight infection by producing antibodies.

PCI-32765 is orally administered and inhibits the Burton's tyrosine kinas (BT) enzyme, which is central to B cell receptor signaling. The drug causes programmed cell death and hinders cell migration and adhesion in malignant B cells.

A Phase III clinical trial is planned. The clinical trial was funded by Pharmacyclics, Inc., the drug's developer.

Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Clinical Trials News

Plant Chloroplasts Offer Hope for  Huntington's Disease Treatment
A chloroplast plant enzyme - stromal processing peptidase, helps treat Huntington's disease by preventing protein clumping.
'Artificial Wombs' In Human Trials Await FDA Approval
FDA approval is sought for “artificial womb” clinical trials (mimicking lamb trials) in humans, that can potentially reduce mortality in premature babies.
Injecting Platelets Could be as Beneficial as Exercising to the Brain
Increasing the levels of platelet-derived factors in the body may lessen the effect of age-related degenerative changes and cognitive impairment in the brain.
Engineered Bacteria Offer New Hope for Early Cancer Detection
Constructing bacteria to become drug resistant only when they took up DNA containing cancer-associated changes, could be useful in detecting cancer.
Is Eli Lilly's Drug the Future of Obesity Treatment?
Eli Lilly's Mounjaro may prove an alternative to bariatric surgery, stated clinical trial results.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Novel Experimental Agent Benefits Chronic Lymphocytic Leukemia Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests